Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's syndrome

Bowman, Simon J., Everett, Colin C., O'Dwyer, John L., Emery, Paul, Pitzalis, Costantino, Ng, Wan‐Fai, Pease, Colin T., Price, Elizabeth J. +15 more·2017·Arthritis & Rheumatology
DOI 10.1002/art.40093

Cited by (276)

Items 101–200 of 276

  1. NKp30 Receptor Upregulation in Salivary Glands of Sjögren’s Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment
    Elena Pontarini, Elisabetta Sciacca, Sofia Grigoriadou, Felice Rivellese, Davide Lucchesi, Liliane Fossati‐Jimack, Rachel Coleby, Farzana Chowdhury, Francesca Calcaterra, Anwar R. Tappuni et al. · 2021 · Frontiers in Immunology
  2. Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept
    Sangwook Oh, Aimee S. Payne · 2022 · Immune Network
  3. Targeted Therapy for Primary Sjögren’s Syndrome: Where are We Now?
    Bin Wang, Shiju Chen, Yan Li, Jingxiu Xuan, Yuan Liu, Guixiu Shi · 2021 · BioDrugs
  4. Toward better outcomes in Sjögren's syndrome: The promise of a stratified medicine approach
    Ghaith Noaiseh, Alan N. Baer · 2020 · Best Practice & Research Clinical Rheumatology
  5. Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome
    Lucas L. van den Hoogen, Jacob M. van Laar · 2020 · Best Practice & Research Clinical Rheumatology
  6. Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation
    Farzana Chowdhury, Anwar R. Tappuni, Michele Bombardieri · 2021 · Frontiers in Medicine
  7. The Future of Targeted Treatment of Primary Sjögren’s Syndrome: A Focus on Extra-Glandular Pathology
    Weizhen Zeng, Xinyao Zhou, Ruihua Liu, Chrystie Wan Ning Quek, Vincent Ho Chit Yu, Ryan Yong Kiat Tay, 于素兰, Bo Yang, Xiang Lin, Yun Feng · 2022 · International Journal of Molecular Sciences
  8. SHED-Derived Exosomes Ameliorate Sjögren’s Syndrome-Induced Hyposalivation by Suppressing Th1 Cell Response via the miR-29a-3p/T-bet Axis
    Zhihao Du, Wei‐Xia Chu, Xin Peng, Li‐Ling Wu, Yan Liu, Guang‐Yan Yu, Chong Ding · 2025 · ACS Applied Materials & Interfaces
  9. Sjögren’s and non-Sjögren’s sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature
    Valentina Pucino, Jason D. Turner, Saba Nayar, Florian Kollert, Saaeha Rauz, Andrea Richards, Jon Higham, Ana Poveda‐Gallego, Simon Bowman, Francesca Barone et al. · 2022 · RMD Open
  10. Mitochondria-related genes and metabolic profiles of innate and adaptive immune cells in primary Sjögren’s syndrome
    Danyang Luo, Lei Li, Yi‐Cheng Wu, Yi Yang, Yulin Ye, Jiawei Hu, Yiming Gao, Naiyan Zeng, Xiaochun Fei, Ning Li et al. · 2023 · Frontiers in Immunology
  11. Recent advances in the search for a targeted immunomodulatory therapy for primary Sjögren’s syndrome
    David L. Leverenz, E. William St. Clair · 2019 · F1000Research
  12. The effects of resistance training in patients with primary Sjogren’s syndrome
    Luciana Paula Dardin, A B Garcia, Paulo Alexandre Minali, Ana Carolina Pereira Nunes Pinto, Virgínia Fernandes Moça Trevisani · 2021 · Clinical Rheumatology
  13. Advances in mesenchymal stem cell-derived extracellular vesicles therapy for Sjogren's syndrome-related dry eye disease
    Sujia Li, Ruijuan Cheng, Shixiong Wei, Zijing Xia, Yaoyu Pu, Yi Liu · 2023 · Experimental Eye Research
  14. Advancement in therapeutic strategies for immune-mediated oral diseases
    Shankargouda Patil, Shazia Mustaq, Jagadish Hosmani, Zafar Ali Khan, Pradeep Kumar Yadalam, Zeeshan Heera Ahmed, Shilpa Bhandi, Kamran Habib Awan · 2022 · Disease-a-Month
  15. Current developments and opportunities of pluripotent stem cells-based therapies for salivary gland hypofunction
    Wenpeng Song, Huan Liu, Yingying Su, Qian Zhao, Xiaoyan Wang, Pengfei Cheng, Hao Wang · 2024 · Frontiers in Cell and Developmental Biology
  16. Correlation Between Subjective and Objective Severity of Oral and Ocular Dryness in Primary Sjögren Syndrome
    David Ripsman, ARTHUR A.M. BOOKMAN · 2021 · The Journal of Rheumatology
  17. Cellular and molecular diversity in Sjogren’s syndrome salivary glands: Towards a better definition of disease subsets
    Elena Pontarini, Rachel Coleby, Michele Bombardieri · 2021 · Seminars in Immunology
  18. Emerging drugs for primary Sjögren’s syndrome
    Saviana Gandolfo, Salvatore De Vita · 2019 · Expert Opinion on Emerging Drugs
  19. Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug?
    Hendrika Bootsma, Frans G. M. Kroese, Arjan Vissink · 2017 · Arthritis & Rheumatology
  20. Primary Sjögren’s Syndrome: A Retrospective Cohort Study of Burden of Illness in Sweden
    Anna Westerlund, Anne Mette Tranberg Kejs, H. Beydogan, Kerry Gairy · 2021 · Rheumatology and Therapy
  21. Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjögren’s syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren’s Syndrome Endocrinopathy) and ROSE II trials
    Hiroto Tsuboi, Hirofumi Toko, Fumika Honda, Saori Abe, Hiroyuki Takahashi, Mizuki Yagishita, Shinya Hagiwara, Ayako Ohyama, Yuya Kondo, Kazuhisa Nakano et al. · 2022 · Modern Rheumatology
  22. French national diagnostic and care protocol for Sjögren's disease
    Valérie Devauchelle‐Pensec, Xavier Mariette A, Anas‐Alexis Benyoussef, Sylvie Boisramé, Béatrice Cochener, Divi Cornec, Gaëtane Nocturne, Jacques‐Eric Gottenberg, Eric HACHULLA, P. Labalette et al. · 2023 · La Revue de Médecine Interne
  23. B Cells Are Indispensable for a Novel Mouse Model of Primary Sjögren’s Syndrome
    Junfeng Zheng, Qiaoniang Huang, Renliang Huang, Fengyuan Deng, Xiaoyang Yue, Junping Yin, Wenjie Zhao, Yan Chen, Lifang Wen, Jun Min Zhou et al. · 2017 · Frontiers in Immunology
  24. Actualités dans le syndrome de Sjögren primitif : aspects cliniques et thérapeutiques
    Gaëtane Nocturne · 2019 · La Revue de Médecine Interne
  25. Efficacy of pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases
    Bayram Farisoğulları, Eduardo José Ferreira Santos, Emma K. Dures, Rinie Geenen, Pedro Machado · 2023 · RMD Open
  26. Emerging biologic frontiers for Sjogren’s syndrome: Unveiling novel approaches with emphasis on extra glandular pathology
    Xiao Li, Maierhaba Maitiyaer, Qing Tan, Wen Hui Huang, Yu Liu, Zhi Ping Liu, Yue Qiang Wen, Yu Zheng, Xing Chen, Rui Lin Chen et al. · 2024 · Frontiers in Pharmacology
  27. Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development
    Foteini Karakontaki, Efstratios Panselinas, Vlasios Polychronopoulos, Athanasios G. Tzioufas · 2020 · Autoimmunity Reviews
  28. Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials
    Robert I. Fox, Carla M. Fox, Sara S. McCoy · 2023 · Expert Opinion on Emerging Drugs
  29. Primary Sjögren’s syndrome: new perspectives on salivary gland epithelial cells
    Jiaqi Hou, Yiyi Feng, Zhixia Yang, Yimei Ding, Dandan Cheng, Zhonghao Shi, Rouxin Li, Luan Xue · 2024 · European journal of medical research
  30. Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren’s Syndrome
    Soledad Retamozo, Chiara Baldini, Hendrika Bootsma, Salvatore De Vita, Thomas Dörner, Benjamin A. Fisher, Jacques‐Eric Gottenberg, Gabriela Hernández‐Molina, Agnes Kocher, Belchin Kostov et al. · 2021 · Drugs & Aging
  31. Sjögren’s syndrome: shedding light on emerging and key drug targets
    Dominic Ridgewell, Nishanthi Thalayasingam, Wan‐Fai Ng · 2022 · Expert Opinion on Therapeutic Targets
  32. Gene Expression Profiles in Primary Sjögren's Syndrome With and Without Systemic Manifestations
    Claudio Vitali, Marzia Dolcino, Nicoletta Del Papa, Antonina Minniti, Francesca Serena Pignataro, Wanda Maglione, Claudio Lunardi, Antonio Puccetti · 2019 · ACR Open Rheumatology
  33. World Workshop on Oral Medicine VIII: Development of a core outcome set for dry mouth: a systematic review of outcome domains for xerostomia
    Paswach Wiriyakijja, Sven Eric Niklander, Alan Roger Santos‐Silva, Michal Kuten‐Shorrer, Melanie Louise Simms, Alessandro Villa, Vidya Sankar, Alexander Ross Kerr, Richeal Ní Ríordáin, Siri Beier Jensen et al. · 2023 · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology
  34. Sjögren‐Syndrom
    Fiona André, Barbara C. Böckle · 2022 · JDDG Journal der Deutschen Dermatologischen Gesellschaft
  35. Identification of outcome domains in primary Sjögren's disease: A scoping review by the OMERACT Sjögren disease working group
    Yann Nguyen, Maxime Beydon, Nathan Foulquier, Rachael A. Gordon, Coralie Bouillot, Katherine M. Hammitt, Simon Bowman, Xavier Mariette A, Sara S. McCoy, Divi Cornec et al. · 2024 · Seminars in Arthritis and Rheumatism
  36. Novel therapies in Sjögren’s disease: A systematic review of the literature
    Cristina Pelkas, Kyle B. Franke, Fabien B. Vincent, Maureen Rischmueller · 2025 · Best Practice & Research Clinical Rheumatology
  37. Effects of Xerostom® products on xerostomia in primary Sjögren’s syndrome: A randomized clinical trial
    Rosa María López‐Pintor, Lucía Ramírez, Julia Serrano, Miguel de Pedro, Mónica Fernández Castro, Elisabeth Casañas, Gonzalo Hernández · 2018 · Oral Diseases
  38. Disease activity and patient reported outcome measures in Sjögren’s – what are the best tools to evaluate?
    Raphaèle Séror, Saaeha Rauz, Marjolaine Gosset, Simon Bowman · 2019 · Lara D. Veeken
  39. Peripheral Neuropathies Associated With Vasculitis and Autoimmune Connective Tissue Disease
    Chafic Karam · 2020 · CONTINUUM Lifelong Learning in Neurology
  40. Novel and potential future therapeutic options in Sjögren's syndrome
    Ting Zhao, Runrun Zhang, Zhaofu Li, Dongdong Qin, Xinchang Wang · 2024 · Heliyon
  41. Primary Sjögren's syndrome: new beginning for evidence-based trials
    Alain Saraux, Valérie Devauchelle‐Pensec · 2021 · The Lancet
  42. Profiles of peripheral B cell subsets in a cohort of primary Sjögren's syndrome patients and their potential clinical significance
    Yixiao Xing, Xiaotian Li, Wei Pan, Hong Hua · 2024 · Journal of Dental Sciences
  43. Evaluation and management of dry mouth and its complications in rheumatology practice
    Zohreh Khavandgar, Blake M. Warner, Alan N. Baer · 2023 · Expert Review of Clinical Immunology
  44. Selection of study endpoints and patients for clinical trials in primary Sjögren's syndrome
    Suzanne Arends, Liseth de Wolff, Liselotte Deroo, Gwenny M. P. J. Verstappen, Arjan Vissink, Frans G. M. Kroese, Dirk Sw Elewaut, Isabelle Peene, Hendrika Bootsma · 2022 · Clinical and Experimental Rheumatology
  45. Outcome Measures in Primary Sjögren’s Syndrome
    Raphaèle Séror, Simon Bowman · 2020 · Arthritis Care & Research
  46. Depression is the most significant independent predictor of fatigue in patients with primary Sjögren’s syndrome
    Koray Ayar, Meliha Kasapoğlu Aksoy, Tülay Dilara Hattatoğlu, Büşra Yeşil · 2023 · Archives of Rheumatology
  47. A Systematic Review of Clinical Trial Designs and Outcome Measures in Sjögren Disease Randomized Controlled Trials
    Maxime Beydon, Yann Nguyen, Rachael A. Gordon, Nathan Foulquier, Coralie Bouillot, Katherine M. Hammitt, Simon Bowman, Xavier Mariette A, Divi Cornec, Sara S. McCoy et al. · 2025 · The Journal of Rheumatology
  48. Unraveling the transcriptome-based network of tfh cells in primary sjogren syndrome: insights from a systems biology approach
    Danyang Luo, Lei Li, Yi Yang, Yulin Ye, Jiawei Hu, Yuan Zong, Jiawen Zhao, Yiming Gao, Haimin Xu, Ning Li et al. · 2023 · Frontiers in Immunology
  49. Recomendaciones SER sobre la utilización de fármacos biológicos en el síndrome de Sjögren primario
    José Luís Andreu, Mónica Fernández Castro, Petra Díaz del Campo Fontecha, Hèctor Corominas, Javier Narváez, José Carlos Rosas Gómez de Salazar, Íñigo Rúa‐Figueroa, Miguel Ángel Abad Hernández, María Noelia Álvarez Rivas, Javier del Pino Montes et al. · 2019 · Reumatología Clínica
  50. Oral dryness and Sjögren's: an update
    Pepe Shirlaw, Amir Khan · 2017 · BDJ
  51. Meta-analysis of the efficacy and safety of rituximab in the treatment of primary Sjögren’s syndrome
    Xiao Zheng, Jiaoyang Di, Xuexiao Chen, Fang Li, Yixuan Liu, Jingjing Cao, Xiaoran Ning, Lin Wei, Guimin Zheng · 2025 · Frontiers in Immunology
  52. Salivary Gland Disorders and Diseases
    Siri Beier Jensen, Arjan Vissink, Norman A. Firth · 2019 · Springer eBooks
  53. Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren's syndrome?
    Esther Mossel, Konstantina Delli, Suzanne Arends, Erlin A. Haacke, Bert van der Vegt, Jolien F. van Nimwegen, Alja J. Stel, Fred K. L. Spijkervet, Arjan Vissink, Frans G. M. Kroese et al. · 2018 · Annals of the Rheumatic Diseases
  54. Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome
    Sophanit Pepple, Jack Arnold, Edward M J Vital, Andy C. Rawstron, Colin Thomas Pease, Shouvik Dass, Paul Emery, Md Yuzaiful Md Yusof · 2022 · ACR Open Rheumatology
  55. Brain mapping inflammatory-arthritis-related fatigue in the pursuit of novel therapeutics
    Kristian Stefanov, Salim Al‐Wasity, Joel T. Parkinson, Gordon D. Waiter, Jonathan Cavanagh, Neil Basu · 2023 · The Lancet Rheumatology
  56. Systemic disease activity measured with ESSDAI varies largely over 5 years in a prospective, longitudinal cohort of patients with Sjögren’s disease
    Liseth de Wolff, Gwenny M. P. J. Verstappen, Alja J. Stel, Greetje S. van Zuiden, Jolien F. van Nimwegen, Arjan Vissink, Frans G. M. Kroese, Suzanne Arends, Hendrika Bootsma · 2025 · RMD Open
  57. Efficacy of early rituximab treatment in primary Sjögren’s syndrome: a systematic review and meta-analysis
    Mohammad Shahdadian, Mohammad Ali Saghiri, Eugenio Capitle · 2025 · Journal of Rheumatic Diseases
  58. Determinants of health-related quality of life across the spectrum of connective tissue diseases using latent profile analysis: results from the LEAP cohort
    Sarah Dyball, John A. Reynolds, Ariane L. Herrick, Sahena Haque, Hector Chinoy, Ellen S. Bruce, Sophia M. Naz, Ben Parker, Ian N Bruce · 2022 · Lara D. Veeken
  59. Research hotspots and emerging trends in the treatment of Sjogren's syndrome: A bibliometric analysis from 1900 to 2022
    Wenpeng Song, Hao Wang, Xiaoyan Wang · 2023 · Heliyon
  60. A Smartphone App to Support Self-Management for People Living With Sjögren's Syndrome: Qualitative Co-Design Workshops
    Claire McCallum, Miglena Campbell, John Vines, Tim Rapley, Jason Gordon Ellis, Vincent Deary, Katie L. Hackett · 2024 · JMIR Human Factors
  61. Challenges in Treatment of Primary Sjögren’s Syndrome and Opportunities for Chinese Medicine
    Jiaqi Hou, Luan Xue · 2019 · Chinese Journal of Integrative Medicine
  62. Fatigue in primary Sjögren's syndrome is associated with an objective decline in physical performance, pain and depression
    Roeland F. Prak, Suzanne Arends, Gwenny M. P. J. Verstappen, Greetje S. van Zuiden, Frans G. M. Kroese, Hendrika Bootsma, Inge Zijdewind · 2022 · Clinical and Experimental Rheumatology
  63. Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting
    Viktoriya Pavlych, Claudia Di Muzio, Alessia Alunno, Francesco Carubbi · 2020 · Frontiers in Medicine
  64. Association of Primary Sjögren’s Syndrome and Vitamin B12 Deficiency: A Cross-Sectional Case-Control Study
    G. Urbanski, Floris Chabrun, Baudouin Schaepelynck, Morgane May, Marianne Loiseau, E. Schlumberger, Estelle Delattre, Christian Lavigne, Valentin Lacombe · 2020 · Journal of Clinical Medicine
  65. Regulatory T cell therapy for Sjögren's disease: From pathogenesis to targeted treatment
    Zhi Feng Sherman Lim, Alberta Yik-Bun Hoi, Fabien B. Vincent, Joshua Daniel Ooi, Eric Francis Morand, Maureen Rischmueller, Yi Tian Ting · 2025 · Journal of Translational Autoimmunity
  66. Pulmonary Manifestations of Sjögren's Disease
    Louise Byrne, Cormac McCarthy, Aurélie Fabre, Nishant Gupta · 2024 · Seminars in Respiratory and Critical Care Medicine
  67. Mycophenolate for the treatment of primary Sjögren’s syndrome
    Weiqian Chen, Jin Lin · 2020 · Journal of Translational Internal Medicine
  68. Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial
    Qin Shao, Liang Jin, Chengyin Li, Jing Wang, Miao Wang, Qin Wang, Bin Wu · 2021 · EXPLORE
  69. Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study
    Alexandre Dumusc, Fahad Alromaih, Matthieu Perreau, Thomas Hügle, Pascal Zufferey, Diana Dan · 2023 · Arthritis Research & Therapy
  70. Insights into Patient Heterogeneity in Sjögren’s Disease
    Lisa Pecorelli, Kerstin Klein · 2025 · International Journal of Molecular Sciences
  71. Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren’s disease
    Baptiste Chevet, Valérie Devauchelle‐Pensec, Elena Pontarini, Valentin M. D. Baloche, Michele Bombardieri, Simon Bowman, Michael Barnes, Antoine G. Sreih, Jinqi Liu, Sheila Kelly et al. · 2025 · Annals of the Rheumatic Diseases
  72. Can we cure Sjogren’s disease? Unmet needs and raising questions in the era of Precision medicine
    Loukas G. Chatzis, Andreas V. Goules, Athanasios G. Tzioufas · 2025 · Current Opinion in Immunology
  73. Instruments for Outcome Evaluation of Specific Domains in Primary Sjögren’s Syndrome
    Nicoletta Del Papa, Antonina Minniti, Wanda Maglione, Francesca Serena Pignataro, Roberto Felice Caporali, Claudio Vitali · 2021 · Biomolecules
  74. Treatment of non-systemic Sjögren's syndrome: Potential prevention of systematization with immunosuppressant agent/biotherapy
    Aude Belbézier, Thi Thu Thuy Nguyen, Mélanie Arnaud, B. Ducotterd, Marie Vangout, Alban Deroux, Catherine Mansard, F. Sarrot-Reynauld, Laurence Bouillet · 2024 · Journal of Translational Autoimmunity
  75. Expert Perspective: Challenges in Sjögren's Disease
    Gaëtane Nocturne, Xavier Mariette A · 2023 · Arthritis & Rheumatology
  76. Connecting salivary gland inflammation to specific symptoms in Sjögren’s disease
    Niels Sluijpers, Sarah A. Pringle, Hendrika Bootsma, Fred K. L. Spijkervet, Arjan Vissink, Konstantina Delli · 2024 · Expert Review of Clinical Immunology
  77. Immune Monitoring upon Treatment with Biologics in Sjögren’s Syndrome: The What, Where, When, and How
    Joyce J. B. C. van Beers, Jan G.M.C. Damoiseaux · 2021 · Biomolecules
  78. New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology
    Xingyu Zhou, Dong Xu, Mengtao Li, Xiaofeng Zeng · 2024 · Expert Opinion on Investigational Drugs
  79. Biologic Therapy in the Treatment of Sjögren’s Syndrome: a Clinical Perspective
    Chadwick R. Johr, Frederick B. Vivino · 2018 · Current Treatment Options in Rheumatology
  80. Can We Expect Any Effect of Rituximab on Fatigue in Primary Sjögren Syndrome?: A Systematic Review and Critical Appraisal.
    An-Marie Hermans, Jean‐Baptiste Vulsteke, Jan Lenaerts, Ellen De Langhe · 2021 · PubMed
  81. FatiguE in Sjögren’s Syndrome: a randomised controlled trial of cOmbined Non-phArmacological therapeutic strategies (FESSONA)
    Xinyao Zhou, Jinzhou Chen, Claire Colas, David Hupin, Martin Killian · 2025 · BMJ Open Sport & Exercise Medicine
  82. Efficacy and safety of iguratimod in patients with primary Sjögren’s syndrome: a multicentre randomised controlled trial
    Xiaochan Chen, Ting Zhang, Lifeng Meng, Cheng Xu, Lichun Jiang, Guofang Wang, Tao Hou, Hongzhi Wang, Yongmei Han, Ying Guan et al. · 2025 · RMD Open
  83. Treatment with a Lactococcus lactis that chromosomally express E. coli cfaI mitigates salivary flow loss in a Sjögren’s syndrome-like disease
    Ali Akgül, Christian Furlan Freguia, Massimo Maddaloni, Carol A. Hoffman, Alexandria Voigt, Cuong Quoc Nguyen, Neil A. Fanger, Gary R. Fanger, David W. Pascual · 2023 · Scientific Reports
  84. Consensus gene modules strategy identifies candidate blood-based biomarkers for primary Sjögren's disease
    Cheïma Boudjeniba, Perrine Soret, Diana Trutschel, Antoine Hamon, Valentin M. D. Baloche, Bastien Chassagnol, Emiko Desvaux, Antoine Bichat, Audrey Aussy, Philippe E. Moingeon et al. · 2024 · Clinical Immunology
  85. Salivary Gland Disorders and Diseases
    Siri Beier Jensen, Arjan Vissink, Norman A. Firth · 2017 · Springer eBooks
  86. Sleep apnea in Sjögren’s syndrome potentially influences the EULAR Sjögren’s syndrome patient reported index
    Maike Jülich, Stephan Budweiser, Jan Thoden, Reinhard Edmund Voll, Florian Kollert · 2018 · Modern Rheumatology
  87. Sjögren's syndrome
    Alexandre Dumusc, Vijay Rao, Simon Bowman · 2018 · Medicine
  88. SER recommendations on the use of biological drugs in primary Sjögren's syndrome
    José Luís Andreu, Mónica Fernández Castro, Petra Díaz del Campo Fontecha, Hèctor Corominas, Francisco Javier Narváez García, José Carlos Rosas Gómez de Salazar, Íñigo Rúa‐Figueroa, Miguel Ángel Abad Hernández, María Noelia Álvarez Rivas, Javier del Pino Montes et al. · 2019 · Reumatología Clínica (English Edition)
  89. Case Report: A case of membranous nephropathy associated with primary Sjögren’s syndrome treated with telitacicept
    Juan Chen, Fangfang Zhou, Jian Shen, Jun Pang, Hanqing Chu · 2025 · Frontiers in Immunology
  90. Assessment of symptoms in myalgic encephalomyelitis/chronic fatigue syndrome: a comparative study of existing scales
    Jing Nan Lu, Weibo Sun, Shulin Li, Yuanyuan Qu, Tingting Liu, Shuhao Guo, Chuwen Feng, Tiansong Yang · 2025 · Frontiers in Neurology
  91. Efficacy and safety of efgartigimod PH20 SC for Sjögren’s disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2, randomized, double-blind, placebo-controlled trial (OASIS study)
    Yushiro Endo, Naoki Hosogaya, Yuri Fukushige, Sawana Narita, Julie Jacobs, William G. Reiss, Yuya Imai, T. Shimizu, Tomohiro Koga, H. Yamamoto et al. · 2026 · Frontiers in Medicine
  92. Activity and Damage Indices for Sjögren’s Disease
    Elodie Portier, Maxime Beydon, Simon Bowman, Raphaèle Séror · 2026 · Journal of Clinical Medicine
  93. Evolution and prospects for the definition of clinically useful endpoints in Sjögren disease
    Maxime Beydon, Simon Bowman, Raphaèle Séror · 2026 · Current Opinion in Immunology
  94. Clinical trials and new therapies in Sjögren’s disease
    Vishal Patel, Antonio Salas, Thomas Grader‐Beck · 2026 · Current Opinion in Immunology
  95. Emerging treatments for Sjögren’s disease: promising drugs on the horizon
    Carlos Marques Gomes, Simon Bowman, Saba Nayar, Benjamin A. Fisher · 2026 · RMD Open
  96. Efficacy of rituximab for glandular Sjö gren's disease according to international clinical trials
    Anna Vasilyevna Torgashina · 2020 · Modern Rheumatology Journal
  97. Maladie de Sjögren : de la physiopathologie aux avancées thérapeutiques
    Xavier Mariette A · 2024 · Biologie Aujourd hui
  98. Improved Fatigue Management in Primary Sjögren’s Syndrome: A Retrospective Analysis of the Efficacy of Methotrexate in Chinese Patients
    Meiju Zhou, Xiaona Dai, Fang Yuan · 2024 · Journal of Inflammation Research
  99. The role of dental professionals in identifying patients with a suspected primary Sjögren's syndrome and suggestions for prevention and treatment of oral complications: a narrative review
    Franck Decup, Rihab Boughanmi, Gaëtane Nocturne, Marjolaine Gosset · 2025 · Heliyon
  100. Treize raisons pour ne pas cibler le lymphocyte B dans le traitement du lupus érythémateux systémique
    L Chiche · 2018 · La Revue de Médecine Interne